AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04229017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior Cervical Stabilization System (PCSS)
Description: Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.
Study NCT04275518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: APG-115 orally once daily from Days 1 to 7 every 28 days.
Study NCT06250075 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formulation with probiotics
Description: Lactobacillus acidophilus NCFM®, Lactobacillus paracasei Lpc-37 ™, Bifidobacterium lactis Bi-04™, Bifidobacterium lactis Bi-07™, Bifidobacterium bifidum Bb-02™)
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20 mg atorvastatin
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20 mg atorvastatin
Study NCT00973271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atorvastatin
Description: 20 mg atorvastatin
Study NCT04275518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 SC QD on Days 1- 7 (28-day cycle)
Study NCT04275518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1g/m\^2 IV QD on Days 3-7 (28-day cycle)
Study NCT03597724 — intervention group
Intervention type: OTHER
Intervention: Questionnaire composed of 13 choice questions.
Description: In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
Study NCT01230671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A 12 week yoga session will be offered to women with breast cancer.
Study NCT02574780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: complex physical therapy
Description: Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
Study NCT02574780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate treatment of lymphedema, with in the quality of life and depression
Description: evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
Study NCT03286569 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper arch Wilson quadhelex appliance
Description: Upper arch Wilson quadhelex appliance
Study NCT03286569 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Upper arch Wilson quadhelex appliance
Description: Upper arch Wilson quadhelex appliance
Study NCT03206450 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and provide saliva and semen samples
Study NCT03206450 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03206450 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04678544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling system 2
Description: The investigational device which will be used in this study is the Paxman Scalp Cooling System 2. This device is manufactured by: Paxman Coolers Limited. This is a free-standing, electrically-powered, mobile refrigeration unit which circulates a refrigerated liquid coolant, at a pre-set temperature and flow rate, through a cooling cap which is attached to, and covers, the top of the patient's head. The Paxman Scalp Cooling System is intended to be used for scalp cooling of patients who are receiving chemotherapy for the treatment of solid tumors, in order to reduce the risk of chemotherapy-induced alopecia.~After the RCT, 34 patients who were expected to receive 4, 6, or 8 cycles of chemotherapy with an anthracycline regimen were further enrolled in the intervention group as a single-arm trial.
Study NCT04606849 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physician Survey
Description: Our questionnaire includes questions on respondent demographics and Likert-style questions about respondent experiences with ePNa. We will validate our modified questionnaire by calculating component loadings and Cronbach Alphas (i.e., internal consistency) of Likert questions loading onto the same components.
Study NCT04606849 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ePNa-CheXED
Description: ePNa-CheXED will incorporate Stanford University's artificial intelligence CheXED model to provide electronic classification of chest images in \<1 second for elements of pneumonia diagnosis and treatment (radiographic pneumonia, single vs multiple lobes, and pleural effusion).
Study NCT04665895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
Description: twice daily inhalation throughout the study
Study NCT04665895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK
Description: twice daily inhalation throughout the study
Study NCT04665895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily inhalation throughout the study
Study NCT02513251 — intervention group
Intervention type: OTHER
Intervention: Chronic pain
Description: Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
Study NCT04025983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GastimunHp Plus
Description: Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
Study NCT04025983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains neither IgY nor L. johnsonii.
Study NCT03476668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT
Description: 4-week multidisciplinary intensive rehabilitation treatment
Study NCT00390598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG (solution given 4 L)
Study NCT00390598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: senna glycoside 36 mg and PEG (solution given 2 L)
Study NCT02073110 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous Optical Biopsy (OCT and DRS)
Study NCT02614651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Find visual comfort threshold related to light intensity
Description: In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally.
Study NCT02614651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Find the size of the visual field
Description: For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
Study NCT02614651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Effectiveness of brightness control
Description: During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object.
Study NCT02614651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Performance of color correction
Description: During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions.
Study NCT02614651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vuzix Wrap 1200DX virtural reality glasses
Description: The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
Study NCT03188627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bronchial basal cells
Description: Transplantation of autologous bronchial basal cells
Study NCT06250075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-intervention for Clinical Outcomes -G5
Description: only observation of clinical outcomes in the postoperative period
Study NCT04255186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal 448 kHz Capacitive Resistive Monopolar Radiofrequency
Description: Thermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
Study NCT04255186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subthermal 448 kHz Capacitive Resistive Monopolar Radiofrequency
Description: Subthermal Application of 448 kHz monopolar radio frequency in capacitive and resistive method
Study NCT04255186 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: a simulated stimulation protocol so that the device does not emit current
Study NCT03924245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given by mouth
Study NCT00368082 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFbeta resistant LMP-specific CTLs
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10\^7 cells/m2 Day 14 2 x 10\^7 cells/m2~Group Two:~Day 0 6 x 10\^7 cells/m2 Day 14 6 x 10\^7 cells/m2~Group Three:~Day 0 1.5 x 10\^8 cells/m2 Day 14 1.5 x 10\^8 cells/m2
Study NCT04326959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium
Description: Injection of Allogeneic Umbilical Cord Mesenchymal Stem Cells 2 million cell/cm3 in Nacl 1 cc/million cell and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
Study NCT04326959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditioned Medium
Description: Injection of Conditioned Medium 1 cc/cm3 and booster with Conditioned Medium 1 cc/cm3 in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
Study NCT04326959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Injection of Triamcinolone Acetonide 40 mg/cc/cm3 and booster in 3 weeks later. All treatment via intralesional injection. The maximum size of the keloid is 15 cm.
Study NCT03796832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flat Flexible Shoes
Description: Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height \<15 mm, (ii) shoe pitch \<10 mm, (iii) absent arch support/motion control, (iv) minimal sole rigidity, (v) weight \<=200g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
Study NCT03796832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stable Supportive Shoes
Description: Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height >30 mm, (ii) shoe pitch >10 mm, (iii) present arch support/motion control, (iv) sole rigidity, (v) weight >300g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
Study NCT03796832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
Study NCT03924245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given by mouth
Study NCT04122924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal muscle training
Description: The intervention starts 6-12 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
Study NCT03545386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: Stool from healthy donor administered via enema
Study NCT03545386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline with food coloring administered via enema
Study NCT03796832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
Study NCT00210132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT03169309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Entrainment Technology
Description: Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
Study NCT03508375 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples
Study NCT03508375 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Description: blood samples
Study NCT03971071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab 70 mg
Description: Erenumab once every 4 weeks. Subcutaneous injection.
Study NCT03971071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab 140 mg
Description: Erenumab once every 4 weeks. Subcutaneous injection.
Study NCT03971071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once every 4 weeks. Subcutaneous injection.
Study NCT00553969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol phosphate
Description: Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
Study NCT00553969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
Study NCT00553969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol phosphate and lisinopril
Description: carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
Study NCT00553969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and placebo
Description: capsule once daily for 9 months; dosage unknown
Study NCT01725607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia combined with dexmedetomidine infusion
Description: general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
Study NCT01725607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia combined with TEA
Description: general anesthesia combined with TEA (Group E)
Study NCT02413177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EEG-no RTNF
Description: All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
Study NCT02413177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EEG-RTNF
Description: All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
Study NCT01276067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg Tablet
Study NCT03024801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma
Description: The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
Study NCT03024801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: The patients with knee cartilage injury were randomized to the normal saline group.
Study NCT05956873 — intervention group
Intervention type: DEVICE
Intervention: REVAR
Description: Endovascular repair of ruptured TAAAs with available technique and devices: endovascular treatments were performed in urgent or emergent setting, compulsory within the first 24 hours, using an off-the-shelf stent grafts, or an available custom-made fenestrated/branched device or a physician-modified endografts with fenestrations/branches or parallel endografting for renal and visceral arteries
Study NCT03956381 — intervention group
Intervention type: DEVICE
Intervention: Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.
Description: The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
Study NCT03956381 — intervention group
Intervention type: DEVICE
Intervention: Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach
Description: The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.